Joshua Brody, MD, discusses key follow-up data from the phase 3 ECHELON-1 trial in classical Hodgkin lymphoma.
Joshua Brody, MD, faculty member, Icahn Genomics Institute, director, Lymphoma and Immunotherapy Program, The Tisch Cancer Institute at Mount Sinai, discusses key follow-up data from the phase 3 ECHELON-1 trial (NCT01712490) in classical Hodgkin lymphoma.
The phase 3 trial compared brentuximab vedotin (Adcetris) plus doxorubicin, vinblastine, and dacarbazine (AVD) with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in the frontline treatment of patients with classical Hodgkin lymphoma.
Previous studies have indicated a potential progression-free survival benefit for patients treated with the study combination, Brody says. However, additional follow-up data from the ECHELON-1 trial further supports the use of frontline brentuximab vedotin, Brody explains. Moreover, a significant overall survival (OS) benefit was observed in patients receiving A+AVD compared with ABVD, Brody adds.
It is important to note that this regimen may not be suitable for all patient subgroups, Brody continues. However, these updated data support further investigation into the regimen and its potential as a new standard of care for patients with classical Hodgkin lymphoma, Brody concludes.